Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG-aptaDiR
- Development stage
- Preclinical
- Lead developer
- Aptadir Therapeutics
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CpG-aptaDiR is a bi-functional synthetic oligonucleotide conjugate designed for the targeted epigenetic immunotherapy of acute myeloid leukemia (AML). It consists of a TLR9-activating CpG oligodeoxynucleotide linked to a DNA methyltransferase 1 (DNMT1)-neutralizing RNA aptamer (aptaDiR). This platform utilizes the CpG moiety to achieve myeloid-selective delivery via TLR9-mediated internalization, while the aptamer component inhibits DNMT1 activity to reverse epigenetic suppression of leukemic differentiation and antigen presentation. By combining DNMT1 inhibition with innate immunostimulation, CpG-aptaDiR aims to eliminate leukemia progenitor/stem cells (LSCs) and enhance antitumor immunity, potentially overcoming resistance to standard hypomethylating agents.
- Other names
- CpG-DNMT1 aptamerCpG-DNMT-1 aptamerCpG-DNMT 1 aptamerCpG-DNMT1 aptCpG-DNMT-1 aptCpG-DNMT 1 aptTLR9 agonist–DNMT1 aptamer conjugate
02
Targets
Beyond the preview
Go deeper on CpG-aptaDiR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG-aptaDiR.